Norges Bank
KROS icon

Norges Bank’s Keros Therapeutics KROS Stock Holding History

Norges Bank’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-64,900
Closed -$1.03M – 1801
2024
Q4 		$1.03M Buy
+64,900
New +$3.37M ﹤0.01% 1758
2024
Q1 		– Sell
-35,700
Closed -$1.42M – 1936
2023
Q4 		$1.42M Sell
35,700
-61,700
-63% -$1.93M ﹤0.01% 1827
2023
Q3 		$3.11M Buy
+97,400
New +$3.64M ﹤0.01% 1771
2021
Q4 		– Sell
-52,700
Closed -$2.08M – 2262
2021
Q3 		$2.08M Buy
+52,700
New +$1.88M ﹤0.01% 2043

Other funds holding KROS

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Norges Bank's KROS Position: Q1 2025 in Review

Norges Bank sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 64,900 shares — an estimated $1.03M sold.

Norges Bank first reported a position in KROS in Q3 2021 and held it in 4 quarters. The position peaked at $3.11M in Q3 2023. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Norges Bank reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Norges Bank sold 64,900 Keros Therapeutics shares in Q1 2025, an estimated $1.03M.
  • Norges Bank first reported a position in Keros Therapeutics in Q3 2021 and held it in 4 quarters.
  • Norges Bank's Keros Therapeutics position peaked at $3.11M in Q3 2023.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.